Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
| Revenue (TTM) | $25.84B |
| Gross Profit (TTM) | $16.95B |
| EBITDA | $7.38B |
| Operating Margin | 27.00% |
| Return on Equity | 16.50% |
| Return on Assets | 8.16% |
| Revenue/Share (TTM) | $67.50 |
| Book Value | $62.54 |
| Price-to-Book | 4.40 |
| Price-to-Sales (TTM) | 4.04 |
| EV/Revenue | 4.528 |
| EV/EBITDA | 16.79 |
| Quarterly Earnings Growth (YoY) | 44.10% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $383.57M |
| Float | $348.14M |
| % Insiders | 5.36% |
| % Institutions | 82.84% |
Volatility is currently contracting
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK).
ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Boston, Massachusetts--(Newsfile Corp. - September 18, 2026) - Block & Leviton is investigating Stryker (NYSE: SYK) for potential securities law violations. Investors who have lost money in their Stryker investment should contact the firm to learn more about how they might recover those losses.
SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
Investors looking for stocks in the Medical - Products sector might want to consider either GE HealthCare Technologies (GEHC) or Stryker (SYK). But which of these two stocks is more attractive to value investors?
New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle System and introducing Hoffmann®LRF smartHEX™ at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecy® Surgical Planning, which has supported patient-specific planning for more than 100,000 ankle cases over 14 years, is now available with the Incompass™ Total Ankle System, giving surgeons access to 3D visualization and both resect-through and pin-through fixation options within a single connected platform.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SYK and any ticker you trade — then tracks every position and per-strategy win rate.
